^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:Hormone Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Breast Cancer
    Title:

    Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis

    Published date:
    01/02/2021
    Excerpt:
    Altogether 9 RCTs enrolling a total of 22,313 postmenopausal women with HR-positive breast cancer were included. Pooled data showed an improvement in DFS when extending endocrine therapy from 5 to 7-8 years (HR = 0.79 [0.69, 0.91]), specifically among those who had been treated with only tamoxifen (HR = 0.40 [0.22, 0.73]) or sequential tamoxifen followed by AI (HR = 0.82 [0.71, 0.95])...
    Secondary therapy:
    Aromatase inhibitor
    DOI:
    10.1007/s12282-020-01196-8
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Breast Cancer
    Title:

    Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis

    Published date:
    01/02/2021
    Excerpt:
    Altogether 9 RCTs enrolling a total of 22,313 postmenopausal women with HR-positive breast cancer were included. Pooled data showed an improvement in DFS when extending endocrine therapy from 5 to 7-8 years (HR = 0.79 [0.69, 0.91]), specifically among those who had been treated with only tamoxifen (HR = 0.40 [0.22, 0.73]) or sequential tamoxifen followed by AI (HR = 0.82 [0.71, 0.95])...
    DOI:
    10.1007/s12282-020-01196-8
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

    Excerpt:
    ...- Female patients with a first primary diagnosis of hormone receptor-positive, HER2- negative unilateral early breast cancer for whom an endocrine treatment is indicated...
    Trial ID:
    CLEAR-B
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

    Excerpt:
    ...Patients pathologically diagnosed with hormone receptor positive invasive breast cancer:...
    Trial ID:
    ASPAIT
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance

    Excerpt:
    ...- Diagnosed with hormone receptor positive invasive breast cancer (estrogen receptor (ER) or progesterone receptor (PR) or both >1%) by core needle biopsy...
    Trial ID:
    POWER PIINC
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

    Excerpt:
    ...- Each tumor must be hormone receptor positive...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study

    Excerpt:
    ...Premenopausal patients with early hormone receptor-positive breast cancer at intermediate to high risk (Low risk is defined as having the following 6 items at the same time: lesion size (pT) in the specimen =35 years old) 3....
    Trial ID:
    NCT05801705
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SG-BCC 2023
    Title:

    P007 Tamoxifen reduced breast cancer recurrence in women with DCIS who underwent mastectomy

    Published date:
    03/15/2023
    Excerpt:
    Patients with HR-positive DCIS treated with tamoxifen following mastectomy showed significant decrease in subsequent breast cancer (HR 0.178; P 0.001)….Adjuvant tamoxifen following mastectomy demonstrated significant reduced recurrence risk in ER-positive DCIS.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Med Case Rep
    Title:

    Dual treatment of acromegaly and hormone-receptor-positive breast cancer with tamoxifen: a case report

    Published date:
    04/29/2021
    Excerpt:
    A 57-year old White female with hormone-receptor-positive breast cancer...she was switched to tamoxifen. Shortly after starting tamoxifen, the patient's musculoskeletal symptoms resolved and her insulin-like growth factor 1 levels normalized. She has remained in remission...
    DOI:
    10.1186/s13256-021-02792-8